Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 02/25/26
U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in AdultsGlobeNewsWire • 02/20/26
Teva Pharmaceutical Industries (TEVA) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 02/20/26
Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & DecisionsSeeking Alpha • 02/20/26
Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results TranscriptSeeking Alpha • 02/17/26
Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease PatientsBenzinga • 02/17/26
Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's diseaseGlobeNewsWire • 02/17/26
Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call TranscriptSeeking Alpha • 01/28/26
Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value StockZacks Investment Research • 01/28/26
Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 01/28/26
Teva Pharma Slides On Light 2026 Outlook Despite Fourth-Quarter BeatInvestors Business Daily • 01/28/26
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value PotentialGlobeNewsWire • 01/28/26
Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'GlobeNewsWire • 01/27/26
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q4 EarningsZacks Investment Research • 01/23/26
Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research • 01/15/26
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of MedicineGlobeNewsWire • 01/14/26